Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

Hamadani, Mehdi; Collins, Graham P.; Caimi, Paolo; Samaniego, Felipe; Spira, Alexander I.; Davies, Andrew; Radford, John; Menne, Tobias; Karnad, Anand B.; Zain, Jasmine; Fields, Paul; Havenith, Karin; Cruz, Hans; He, Shui; Boni, Joseph; Feingold, Jay; Wuerthner, Jens; Horwitz, Steven M.

doi:10.1016/s2352-3026(21)00103-4

Cited by 61 publications

(42 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its mechanism of action relates to cell death by cross-linkage to DNA and blockage of DNA replication. Early results show antitumoral activity in both classical Hodgkin lymphoma and non-Hodgkin lymphoma, including PTCL [ 63 ].…”

Section: Biomarkers As Therapeutic Targets For Peripheral T-cell Lymp...mentioning

confidence: 99%

Genetic Landscape of Peripheral T-Cell Lymphoma

Hathuc

Kreisel

2022

Life

View full text Add to dashboard Cite

Peripheral T-Cell lymphoma (PTCL) comprises a heterogenous group of uncommon lymphomas derived from mature, post-thymic or “peripheral” T- and natural killer cells. The World Health Organization (WHO) emphasizes a multiparameter approach in the diagnosis and subclassification of these neoplasms, integrating clinical, morphologic, immunophenotypic, and genetic features into the final diagnosis. Clinical presentation is particularly important due to histologic, immunophenotypic and genetic variations within established subtypes, and no convenient immunophenotypic marker of monoclonality exists. In recent years, widespread use of gene expression profiling and next-generation sequencing (NGS) techniques have contributed to an improved understanding of the pathobiology in PTCLs, and these have been incorporated into the 2016 revised WHO classification of mature T- and NK-cell neoplasms which now encompasses nearly 30 distinct entities. This review discusses the genetic landscape of PTCL and its role in subclassification, prognosis, and potential targeted therapy. In addition to discussing T-Cell lymphoma subtypes with relatively well-defined or relevant genetic aberrancies, special attention is given to genetic advances in T-Cell lymphomas of T follicular helper cell (TFH) origin, highlighting genetic overlaps between angioimmunoblastic T-Cell lymphoma (AITL), follicular T-Cell lymphoma, and nodal peripheral T-Cell lymphoma with a TFH phenotype. Furthermore, genetic drivers will be discussed for ALK-negative anaplastic large cell lymphomas and their role in differentiating these from CD30+ peripheral T-Cell lymphoma, not otherwise specified (NOS) and primary cutaneous anaplastic large cell lymphoma. Lastly, a closer look is given to genetic pathways in peripheral T-Cell lymphoma, NOS, which may guide in teasing out more specific entities in a group of T-Cell lymphomas that represents the most common subcategory and is sometimes referred to as a “wastebasket” category.

show abstract

Section: Biomarkers As Therapeutic Targets For Peripheral T-cell Lymp...mentioning

confidence: 99%

Genetic Landscape of Peripheral T-Cell Lymphoma

Hathuc

Kreisel

2022

Life

View full text Add to dashboard Cite

show abstract

“…Nivolumab, Pembrolizumab, Sintilimab, Tislelizumab, which are anti-PD1 antibodies, have been respectively evaluated in the Checkmate 205 [50], KEYNOTE-087 [51], ORIENT-1 [52] and BGB-A317-203 [53] trials with overall response rates (ORR) of 69%, 72%, 80% and 86%, respectively. Other notable immunotherapies currently under investigation for r/r HL include Camidanlumab Tesirine, an anti-CD25 antibody-drug conjugate, associated with an ORR of 71% [54], and AFM13, a CD16A/CD30 bispecific antibody, which yielded an ORR of 83% in combination with Pembrolizumab [55]. Finally, Ramos et al [13] reported on a cohort of 41 patients a promising 94% 1-year OS following administration of anti-CD30 car-T cells after fludarabine-based lymphodepletion.…”

Section: Development Of New Effective Systemic Treatmentsmentioning

confidence: 99%

Development and Implementation of Proton Therapy for Hodgkin Lymphoma: Challenges and Perspectives

Loap

Marzi

Mirandola

et al. 2021

Cancers

View full text Add to dashboard Cite

Consolidative radiation therapy for early-stage Hodgkin lymphoma (HL) improves progression-free survival. Unfortunately, first-generation techniques, relying on large irradiation fields, were associated with an increased risk of secondary cancers, and of cardiac and lung toxicity. Fortunately, the use of smaller target volumes combined with technological advances in treatment techniques currently allows efficient organs-at-risk sparing without altering tumoral control. Recently, proton therapy has been evaluated for mediastinal HL treatment due to its potential to significantly reduce the dose to organs-at-risk, such as cardiac substructures. This is expected to limit late radiation-induced toxicity and possibly, second-neoplasm risk, compared with last-generation intensity-modulated radiation therapy. However, the democratization of this new technique faces multiple issues. Determination of which patient may benefit the most from proton therapy is subject to intense debate. The development of new effective systemic chemotherapy and organizational, societal, and political considerations might represent impediments to the larger-scale implementation of HL proton therapy. Based on the current literature, this critical review aims to discuss current challenges and controversies that may impede the larger-scale implementation of mediastinal HL proton therapy.

show abstract

“…Nevertheless, in spite the advent of haploidentical HCT with a potential curative effect comparable to that of allo-HCT from identical siblings and matched unrelated donors (118), the number of allografted patients is steadily declining. Combination of new drugs could be the trump card for a less toxic and very active rescue treatment in this setting (119)(120)(121).…”

Section: Relapsedmentioning

confidence: 99%

Hodgkin Lymphoma: Recent Progress in Overall Management

El-Galaly,

Cottereau,

Condoluci

et al. 2021

Lymphoma

View full text Add to dashboard Cite

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

Cited by 61 publications

References 29 publications

Genetic Landscape of Peripheral T-Cell Lymphoma

Genetic Landscape of Peripheral T-Cell Lymphoma

Development and Implementation of Proton Therapy for Hodgkin Lymphoma: Challenges and Perspectives

Hodgkin Lymphoma: Recent Progress in Overall Management

Contact Info

Product

Resources

About